Lupin links with Polish firm to jumpstart Advair generic plans

Lupin has unveiled plans for a significant step up in the inhalation therapy segment, with back-to-back announcements on its efforts for a generic version of GlaxoSmithKline's blockbuster asthma/COPD product, Advair/Seretide (salmeterol/fluticasone), and the launch in the US of a device to enhance delivery of aerosol therapies.

Lupin has unveiled plans for a significant step up in the inhalation therapy segment, with back-to-back announcements on its efforts for a generic version of GlaxoSmithKline's blockbuster asthma/COPD product, Advair/Seretide (salmeterol/fluticasone), and the launch in the US of a device to enhance delivery of aerosol therapies.

Several firms including Sandoz, Mylan and Cipla are already entrenched in the generic Advair space though Lupin expects its deal...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip